PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
PMV Pharmaceuticals reports 46% ORR in Phase 2 trial for ovarian cancer drug rezatapopt. NDA submission planned for Q1 2027.
PMV Pharma raised money to keep developing a new cancer medicine that showed promise in early tests. When a company raises funds and has a plan to submit their drug for approval, it means they believe in their medicine and are moving forward.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.